Targets › CD123
11 programs from 10 companies in 11 trials: 11 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on CD123, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MacroGenics | MGD024 CD123 x CD3 bispecific DART molecule | CD123, CD3 | Phase 1 | Leukemia, Acute Myeloid | Nov 2026 |
| Essen Biotech | CD123/CD33 CAR-T (EB-BH2025) CAR-T cells targeting CD123 and/or CD33 sequentially | CD123, CD33 | Phase 1 | AML | Dec 2026 |
| Xuzhou Medical University | anti Tim-3/CD123 CAR-T cell therapy Dual-targeted CAR-T cell therapy targeting Tim-3 and CD123 | HAVCR2, CD123 | Phase 1 | Acute Myeloid Leukemia Refractory | Jan 2027 |
| AvenCell Europe | Allo-RevCAR01-T-CD123 Allogeneic multi-edited CAR-T cells with reversed CAR (RevCAR) bridged to CD123 via R-TM12 | CD123 | Phase 1 | Acute Myeloid Leukemia, in Relapse | May 2027 |
| Chongqing Precision Biotech | Anti-CD123 CAR NK cells anti-CD123 CAR-NK cells | CD123 | Phase 1 | AML (Acute Myeloid Leukemia) | Jun 2027 |
| City of Hope Medical Center | Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes CD123-targeted allogeneic CAR-T cell therapy with CD28 costimulatory domain | CD123 | Phase 1 | Adult Acute Myeloid Leukemia in Remission | Jul 2027 |
| City of Hope Medical Center | Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes CD123-targeted CAR-T cell therapy with CD28 costimulatory domain | CD123 | Phase 1 | Adult Acute Myeloid Leukemia in Remission | Jul 2027 |
| University of Pennsylvania | CART123 Cells CAR-T cell therapy targeting CD123-expressing cells | CD123 | Phase 1 | Relapsed AML | Mar 2045 |
| Chunji Gao | Donor-derived CD123-CD16 bispecific antibody-modified NK cells CD123-CD16 bispecific antibody-modified NK cells for AML targeting | CD123, FCGR3A | Phase 1 | AML (Acute Myelogenous Leukemia) | – |
| Gilead Sciences | SPRX002 Soluble protein antigen-receptor X-linker with CD123-targeting binding region; serves as b | CD123 | Phase 1 | Acute Myeloid Leukemia | – |
| Cellectis | UCART123v1.2 Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor | CD123 | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia | – |
Adult Acute Myeloid Leukemia in Remission (2) AML (Acute Myeloid Leukemia) (1) Relapsed/Refractory Acute Myeloid Leukemia (1) AML (Acute Myelogenous Leukemia) (1) Relapsed AML (1) Acute Myeloid Leukemia (1) Acute Myeloid Leukemia, in Relapse (1) AML (1) Acute Myeloid Leukemia Refractory (1) Leukemia, Acute Myeloid (1)
other (4), mixed (4), small molecule (2), protein or peptide (1)
City of Hope Medical Center (2) Chongqing Precision Biotech (1) Cellectis (1) Chunji Gao (1) University of Pennsylvania (1) Gilead Sciences (1) AvenCell Europe (1) Essen Biotech (1) Xuzhou Medical University (1) MacroGenics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.